These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11751123)

  • 1. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.
    Pavia C; Inchiosa MA; Wormser GP
    Antimicrob Agents Chemother; 2002 Jan; 46(1):132-4. PubMed ID: 11751123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.
    Yrjänäinen H; Hytönen J; Song XY; Oksi J; Hartiala K; Viljanen MK
    J Infect Dis; 2007 May; 195(10):1489-96. PubMed ID: 17436229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.
    Pavia CS; Wormser GP; Nowakowski J; Cacciapuoti A
    Antimicrob Agents Chemother; 2001 Mar; 45(3):936-7. PubMed ID: 11181384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.
    Wu X; Sharma B; Niles S; O'Connor K; Schilling R; Matluck N; D'Onofrio A; Hu LT; Lewis K
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126963
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment.
    Yrjänäinen H; Hytönen J; Hartiala P; Oksi J; Viljanen MK
    APMIS; 2010 Sep; 118(9):665-73. PubMed ID: 20718718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic treatment in mice infected with Japanese Borrelia garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites.
    Konishi T; Nakao M
    Microbiol Immunol; 1997; 41(2):165-8. PubMed ID: 9087959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.
    Kazragis RJ; Dever LL; Jorgensen JH; Barbour AG
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2632-6. PubMed ID: 8913478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generality of Post-Antimicrobial Treatment Persistence of
    Hodzic E; Imai DM; Escobar E
    Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31308087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design.
    Wormser GP; Baker PJ; O'Connell S; Pachner AR; Schwartz I; Shapiro ED
    Vector Borne Zoonotic Dis; 2012 Jul; 12(7):535-8. PubMed ID: 22620495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythema migrans after ceftriaxone treatment of aseptic meningitis caused by Borrelia burgdorferi.
    Jhaveri R; Cherry JD; Phillips S; Korb J
    Pediatr Infect Dis J; 2001 Oct; 20(10):1010-2. PubMed ID: 11642622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decorin binding proteins of Borrelia burgdorferi promote arthritis development and joint specific post-treatment DNA persistence in mice.
    Salo J; Jaatinen A; Söderström M; Viljanen MK; Hytönen J
    PLoS One; 2015; 10(3):e0121512. PubMed ID: 25816291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice.
    Hodzic E; Imai D; Feng S; Barthold SW
    PLoS One; 2014; 9(1):e86907. PubMed ID: 24466286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease.
    Pothineni VR; Parekh MB; Babar MM; Ambati A; Maguire P; Inayathullah M; Kim KM; Tayebi L; Potula HS; Rajadas J
    Drug Des Devel Ther; 2018; 12():2915-2921. PubMed ID: 30254421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease.
    Dattwyler RJ; Luft BJ; Kunkel MJ; Finkel MF; Wormser GP; Rush TJ; Grunwaldt E; Agger WA; Franklin M; Oswald D; Cockey L; Maladorno D
    N Engl J Med; 1997 Jul; 337(5):289-94. PubMed ID: 9233865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.
    Moody KD; Adams RL; Barthold SW
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1567-72. PubMed ID: 7979290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of third-generation cephalosporins. Spirochetes.
    Luft B; Mariuz P
    Hosp Pract (Off Ed); 1991; 26 Suppl 4():34-9; discussion 53-4. PubMed ID: 1918214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.
    Pavia CS; Wormser GP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6701-3. PubMed ID: 25155590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.
    Sharma B; Brown AV; Matluck NE; Hu LT; Lewis K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4616-24. PubMed ID: 26014929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylactoid reaction caused by sodium ceftriaxone in two horses experimentally infected by Borrelia burgdorferi.
    Basile RC; Rivera GG; Del Rio LA; de Bonis TC; do Amaral GP; Giangrecco E; Ferraz G; Yoshinari NH; Canola PA; Queiroz Neto A
    BMC Vet Res; 2015 Aug; 11():197. PubMed ID: 26265349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure.
    Feng J; Li T; Yee R; Yuan Y; Bai C; Cai M; Shi W; Embers M; Brayton C; Saeki H; Gabrielson K; Zhang Y
    Discov Med; 2019 Mar; 27(148):125-138. PubMed ID: 30946803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.